MX2022008302A - Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina. - Google Patents
Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina.Info
- Publication number
- MX2022008302A MX2022008302A MX2022008302A MX2022008302A MX2022008302A MX 2022008302 A MX2022008302 A MX 2022008302A MX 2022008302 A MX2022008302 A MX 2022008302A MX 2022008302 A MX2022008302 A MX 2022008302A MX 2022008302 A MX2022008302 A MX 2022008302A
- Authority
- MX
- Mexico
- Prior art keywords
- ankyrin repeat
- designed ankyrin
- binding specificity
- serum albumin
- repeat domains
- Prior art date
Links
- 102000008102 Ankyrins Human genes 0.000 title abstract 9
- 108010049777 Ankyrins Proteins 0.000 title abstract 9
- 102000007562 Serum Albumin Human genes 0.000 title abstract 4
- 108010071390 Serum Albumin Proteins 0.000 title abstract 4
- 102000023732 binding proteins Human genes 0.000 abstract 5
- 108091008324 binding proteins Proteins 0.000 abstract 5
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 abstract 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 abstract 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15162502 | 2015-04-02 | ||
| EP15162511 | 2015-04-02 | ||
| PCT/EP2016/057272 WO2016156596A1 (en) | 2015-04-02 | 2016-04-01 | Designed ankyrin repeat domains with binding specificity for serum albumin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022008302A true MX2022008302A (es) | 2023-02-28 |
Family
ID=55650423
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022008302A MX2022008302A (es) | 2015-04-02 | 2016-04-01 | Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina. |
| MX2017012485A MX393655B (es) | 2015-04-02 | 2016-04-01 | Dominios dise?ados con repeticiones de anquirina con especificidad de union para la seroalbumina |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017012485A MX393655B (es) | 2015-04-02 | 2016-04-01 | Dominios dise?ados con repeticiones de anquirina con especificidad de union para la seroalbumina |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9458211B1 (enExample) |
| EP (2) | EP4272838A3 (enExample) |
| JP (1) | JP6552636B2 (enExample) |
| KR (2) | KR102427117B1 (enExample) |
| CN (1) | CN107454904A (enExample) |
| AU (3) | AU2016240220B2 (enExample) |
| BR (1) | BR112017020986A2 (enExample) |
| CA (1) | CA2979602C (enExample) |
| CL (1) | CL2017002454A1 (enExample) |
| CO (1) | CO2017009954A2 (enExample) |
| ES (1) | ES2953482T3 (enExample) |
| IL (2) | IL276944B (enExample) |
| MX (2) | MX2022008302A (enExample) |
| MY (1) | MY179505A (enExample) |
| NZ (1) | NZ735803A (enExample) |
| PH (1) | PH12017501792B1 (enExample) |
| RU (1) | RU2769470C2 (enExample) |
| SA (1) | SA517390092B1 (enExample) |
| SG (1) | SG11201707606RA (enExample) |
| WO (1) | WO2016156596A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2008012991A (es) | 2006-04-07 | 2008-10-17 | Procter & Gamble | Anticuerpos que ligan proteina tirosina fosfatasa humana beta (hptpbeta) y los usos de estos. |
| CN103403024B (zh) * | 2010-11-26 | 2017-08-11 | 分子组合公司 | 设计的锚蛋白重复蛋白的改进的n‑端加帽模块 |
| MX363351B (es) | 2011-10-13 | 2019-03-20 | Aerpio Therapeutics Inc | Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular. |
| EP3487518A4 (en) | 2016-07-20 | 2020-08-12 | Aerpio Therapeutics LLC | HUMANIZED MONOCLONAL ANTIBODIES TARGETING VE-PTP (HPTP-SS) |
| EP3515933B9 (en) * | 2016-09-22 | 2023-08-16 | Molecular Partners AG | Recombinant binding proteins and their use |
| CN110959015B (zh) * | 2017-07-12 | 2023-07-25 | 四川科伦博泰生物医药股份有限公司 | 双特异性重组蛋白 |
| KR20200038303A (ko) * | 2017-08-18 | 2020-04-10 | 캠브리지 엔터프라이즈 리미티드 | 모듈형 결합 단백질 |
| JP7695187B2 (ja) | 2018-09-24 | 2025-06-18 | アイポイント ファーマシューティカルズ， インコーポレイテッド | ＨＰＴＰ－β（ＶＥ－ＰＴＰ）およびＶＥＧＦを標的にする多特異性抗体 |
| CN119930814A (zh) * | 2019-03-22 | 2025-05-06 | 反射制药有限公司 | 针对vegf的d-肽化合物 |
| US20220298212A1 (en) | 2019-06-04 | 2022-09-22 | Molecular Partners Ag | Recombinant 4-1bb binding proteins and their use |
| UY38739A (es) * | 2019-06-04 | 2020-12-31 | Molecular Partners Ag | Proteínas multiespecíficas |
| WO2020245171A1 (en) | 2019-06-04 | 2020-12-10 | Molecular Partners Ag | Designed ankyrin repeat domain with improved stability |
| US20220242973A1 (en) * | 2019-06-04 | 2022-08-04 | Molecular Partners Ag | Recombinant fap binding proteins and their use |
| BR112022011456A2 (pt) * | 2019-12-11 | 2022-08-23 | Molecular Partners Ag | Proteínas recombinantes de ligação a complexo de peptídeo-mhc e geração e uso das mesmas |
| CN114945584A (zh) | 2019-12-11 | 2022-08-26 | 分子合作伙伴股份公司 | 重组肽-mhc复合物结合蛋白及其生成和用途 |
| TW202208404A (zh) | 2020-05-06 | 2022-03-01 | 瑞士商分子組合公司 | 新穎錨蛋白重複結合蛋白質及其用途 |
| WO2021229076A1 (en) * | 2020-05-14 | 2021-11-18 | Molecular Partners Ag | Recombinant cd40 binding proteins and their use |
| US20240279290A1 (en) | 2020-05-14 | 2024-08-22 | Molecular Partners Ag | Multispecific proteins |
| EP3957649A1 (en) | 2020-08-18 | 2022-02-23 | Athebio AG | Improved n-terminal capping modules of ankyrin repeat domains |
| IL303629A (en) | 2020-12-16 | 2023-08-01 | Molecular Partners Ag | Recombinant cd3 binding proteins and their use |
| US20240108746A1 (en) * | 2020-12-16 | 2024-04-04 | Molecular Partners Ag | Novel slow-release prodrugs |
| CA3211381A1 (en) | 2021-03-09 | 2022-09-15 | Matteo Bianchi | Novel darpin based multi-specific t-cell engagers |
| AU2022233791A1 (en) | 2021-03-09 | 2023-09-28 | Molecular Partners Ag | Novel darpin based cd123 engagers |
| JP2024508969A (ja) | 2021-03-09 | 2024-02-28 | モレキュラー パートナーズ アクチェンゲゼルシャフト | 新規のＤＡＲＰｉｎに基づくＣＤ３３エンゲージャ |
| WO2022190008A1 (en) | 2021-03-09 | 2022-09-15 | Molecular Partners Ag | Protease cleavable prodrugs |
| CN118354784A (zh) | 2021-12-14 | 2024-07-16 | 分子合作伙伴股份公司 | 具有双重结合特异性的经设计的重复结构域及其用途 |
| CN114957426B (zh) * | 2022-06-02 | 2023-05-16 | 华南师范大学 | Sp6rars及其在防治蜚蠊目昆虫中的应用 |
| AU2023317655A1 (en) | 2022-08-01 | 2025-01-23 | Molecular Partners Ag | Charge modified designed repeat domains and their use |
| WO2024038307A1 (en) | 2022-08-19 | 2024-02-22 | Novartis Ag | Dosing regimens for sars-cov-2 binding molecules |
| TW202448926A (zh) | 2023-02-17 | 2024-12-16 | 比利時商艾伯霖克斯公司 | 結合新生兒fc受體之多肽 |
| WO2024179981A1 (en) | 2023-02-27 | 2024-09-06 | Molecular Partners Ag | Darpins for use in reducing renal accumulation of drugs |
| WO2024251628A1 (en) | 2023-06-06 | 2024-12-12 | Molecular Partners Ag | Recombinant cd16a binding proteins and their use |
| WO2024251742A1 (en) | 2023-06-06 | 2024-12-12 | Molecular Partners Ag | Recombinant cd2 binding proteins and their use |
| WO2024251695A1 (en) | 2023-06-06 | 2024-12-12 | Molecular Partners Ag | Recombinant cd47 binding proteins and their use |
| WO2025073871A1 (en) | 2023-10-03 | 2025-04-10 | Bicycletx Limited | Bicyclic peptide ligand complexes specific for tfr1 |
| WO2025146490A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Recombinant cd117 binding proteins and their use |
| WO2025146491A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent |
| WO2025146487A1 (en) | 2024-01-05 | 2025-07-10 | Molecular Partners Ag | Multispecific binding proteins |
| WO2025163144A1 (en) | 2024-01-31 | 2025-08-07 | Molecular Partners Ag | Recombinant mesothelin binding proteins and their use |
| US20250332297A1 (en) | 2024-01-31 | 2025-10-30 | Molecular Partners Ag | Dll3-specific binding constructs and their use in radiotherapy |
| WO2025181039A1 (en) | 2024-03-01 | 2025-09-04 | Molecular Partners Ag | Therapeutic combinations comprising a multi-specific t cell engager |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| ATE448301T1 (de) | 2000-09-08 | 2009-11-15 | Univ Zuerich | Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| EA013615B1 (ru) | 2004-11-12 | 2010-06-30 | Байер Шеринг Фарма Акциенгезельшафт | Рекомбинантный онколитический парамиксовирус и его применение |
| EP3613767A1 (en) | 2005-05-18 | 2020-02-26 | Ablynx N.V. | Improved nanobodiestm against tumor cecrosis factor-alpha |
| JP5042218B2 (ja) | 2005-07-08 | 2012-10-03 | ユニバーシティ・オブ・チューリッヒ | 融合ポリペプチドの翻訳と同時のトランスロケーションを使用するファージディスプレイ |
| CA2644712C (en) | 2006-03-06 | 2016-09-13 | Amunix, Inc. | Unstructured recombinant polymers and uses thereof |
| CN101970678B (zh) | 2007-06-21 | 2014-08-20 | 慕尼黑科技大学 | 具有增加的体内和/或体外稳定性的生物学活性蛋白 |
| EP2198022B1 (en) | 2007-09-24 | 2024-03-06 | University Of Zurich | Designed armadillo repeat proteins |
| CA2742241C (en) | 2008-11-03 | 2019-12-10 | Molecular Partners Ag | Binding proteins inhibiting the vegf-a receptor interaction |
| CN102781959A (zh) | 2010-02-05 | 2012-11-14 | 埃博灵克斯股份有限公司 | 能够结合血清白蛋白的肽和包含所述肽的化合物、构建体和多肽 |
| AR081361A1 (es) | 2010-04-30 | 2012-08-29 | Molecular Partners Ag | Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a |
| DK2590993T3 (en) * | 2010-07-09 | 2015-06-29 | Affibody Ab | Polypeptides |
| BR112013001429A2 (pt) * | 2010-07-19 | 2016-05-31 | Hoffmann La Roche | método de identificação de pacientes com maior probabilidade de responder a terapia anticâncer |
| BR112013013003A2 (pt) | 2010-11-24 | 2016-08-09 | Glaxo Group Ltd | proteína de ligação de antígeno, e, composição farmacêutica |
| CN103403024B (zh) | 2010-11-26 | 2017-08-11 | 分子组合公司 | 设计的锚蛋白重复蛋白的改进的n‑端加帽模块 |
| EA201391607A1 (ru) | 2011-04-29 | 2014-04-30 | Янссен Байотек, Инк. | Связывающие il4/il13 белки с повторами и их применение |
| MX2014015825A (es) | 2012-06-28 | 2015-08-10 | Molecular Partners Ag | Proteinas de repeticion de anquirina diseñadas que se unen al factor de crecimiento derivado de plaquetas. |
| EP2738180A1 (en) * | 2012-11-30 | 2014-06-04 | Molecular Partners AG | Binding proteins comprising at least two binding domains against HER2. |
| EP3004152B1 (en) * | 2013-05-31 | 2020-09-30 | Molecular Partners AG | Designed ankyrin repeat proteins binding to hepatocyte growth factor |
-
2016
- 2016-04-01 BR BR112017020986-1A patent/BR112017020986A2/pt not_active Application Discontinuation
- 2016-04-01 MX MX2022008302A patent/MX2022008302A/es unknown
- 2016-04-01 EP EP23177745.9A patent/EP4272838A3/en active Pending
- 2016-04-01 US US15/089,014 patent/US9458211B1/en active Active
- 2016-04-01 KR KR1020177030096A patent/KR102427117B1/ko active Active
- 2016-04-01 EP EP16713904.7A patent/EP3277711B9/en active Active
- 2016-04-01 PH PH1/2017/501792A patent/PH12017501792B1/en unknown
- 2016-04-01 RU RU2017134456A patent/RU2769470C2/ru active
- 2016-04-01 MX MX2017012485A patent/MX393655B/es unknown
- 2016-04-01 AU AU2016240220A patent/AU2016240220B2/en not_active Ceased
- 2016-04-01 CN CN201680019907.XA patent/CN107454904A/zh active Pending
- 2016-04-01 SG SG11201707606RA patent/SG11201707606RA/en unknown
- 2016-04-01 KR KR1020227025940A patent/KR20220109488A/ko not_active Ceased
- 2016-04-01 NZ NZ735803A patent/NZ735803A/en not_active IP Right Cessation
- 2016-04-01 MY MYPI2017703637A patent/MY179505A/en unknown
- 2016-04-01 WO PCT/EP2016/057272 patent/WO2016156596A1/en not_active Ceased
- 2016-04-01 ES ES16713904T patent/ES2953482T3/es active Active
- 2016-04-01 JP JP2017551176A patent/JP6552636B2/ja active Active
- 2016-04-01 CA CA2979602A patent/CA2979602C/en active Active
- 2016-04-01 IL IL276944A patent/IL276944B/en unknown
- 2016-08-26 US US15/248,731 patent/US10155791B2/en active Active
-
2017
- 2017-09-28 IL IL254788A patent/IL254788B/en active IP Right Grant
- 2017-09-28 CL CL2017002454A patent/CL2017002454A1/es unknown
- 2017-09-29 CO CONC2017/0009954A patent/CO2017009954A2/es unknown
- 2017-10-02 SA SA517390092A patent/SA517390092B1/ar unknown
-
2018
- 2018-11-02 US US16/178,923 patent/US11332501B2/en active Active
-
2020
- 2020-02-21 AU AU2020201264A patent/AU2020201264A1/en not_active Abandoned
-
2021
- 2021-12-17 AU AU2021286418A patent/AU2021286418B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA517390092B1 (ar) | مجالات تكرار أنكيرين مصمَّمة ذات نوعية ربط تجاه ألبومين مصل | |
| PH12019500596A1 (en) | Recombinant binding proteins and their use | |
| MX2022007122A (es) | Dominios de repetición de anquirina diseñados con residuos de superficie alterados. | |
| MX2024005945A (es) | Polipeptidos que se unen al componente del complemento c5 o albumina serica y proteinas de fusion de los mismos. | |
| EA201892691A1 (ru) | Однодоменный белок, связывающий сывороточный альбумин | |
| GEP20227447B (en) | Constructs having sirp-alpha domain or variant thereof | |
| HK1258509A1 (zh) | Gitr激动剂 | |
| MX2021006615A (es) | Proteinas de union triespecificas y metodos de uso. | |
| BR112017015567A2 (pt) | proteína gl de citomegalovírus recombinante ou fragmento de formação de complexo da mesma, complexo de citomegalovírus, ácido nucleico isolado, célula hospedeira, e, composição imunogênica | |
| PH12017500834A1 (en) | Methods and formulations for treating vascular eye diseases | |
| WO2015109124A3 (en) | Immunomodulatory agents | |
| MX2022013945A (es) | Nuevas proteinas de union a repeticiones de anquirina y sus usos. | |
| EA201890355A1 (ru) | Новые способы индукции иммунного ответа | |
| EA201491644A1 (ru) | Фармацевтические композиции | |
| MX2021014649A (es) | Dominio de repetición de anquirina diseñado con estabilidad mejorada. | |
| EA201792466A1 (ru) | АНТИТЕЛА ПРОТИВ FcRn | |
| BR112016023519A2 (pt) | inibidor de sinalização de wnt/ß-catenina, composição farmacêutica e método de tratamento e/ou prevenção de uma patologia definida por malformação vascular | |
| ZA202403355B (en) | Single domain antibodies binding to tetanus neurotoxin | |
| EP3956350C0 (en) | MODIFIED CRY PROTEINS FOR DELIVERY OF THERAPEUTIC AGENTS | |
| NZ727444A (en) | Prohemostatic proteins for the treatment of bleeding | |
| BR112019005959A2 (pt) | gene dgkk recombinante para terapia genética da síndrome do x frágil | |
| CA3009928A1 (en) | Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine |